USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
GLIATECH, INC.
Address:
GLIATECH, INC.
23420 COMMERCE PARK RD
CLEVELAND, OH 44122
Phone:
(216) 831-3200
URL:
N/A
EIN:
341728626
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,091,889.00 13
SBIR Phase II $2,093,044.00 3

Award List:

ARTIFICIAL NERVE GRAFT FOR PERIPHERAL NERVE REPAIR

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$49,302.00
Agency:
HHS
Principal Investigator:
Jerome Wujek
Abstract:
This project's objective is to develop an artificial nerve graft for repair of peripheral nerve injuries. this graft will consist of the patient's own schwann cells seeded into a polymer tube to be implanted into nerve gaps. this product will aid in restoring neurological function for the… More

GLIAL ANTIPROLIFERATIVE FACTOR AS A TUMOROSTATIC AGENT

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Dianne Lorton
Abstract:
Malignant gliomas are the most commonly occurring cerebral neoplasms in humans. the incidence of primary brain tumors is 16,000 cases annually, with malignant gliomas (glioblastoma multiforms) comprising 20-40% of these cases. despite concentrated research efforts, the outlook for glioma patients… More

INHIBITORS OF A GLIAL ANTIPROIFERATIVE FACTOR

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
George T Coker Iii
Abstract:
Each year 300,000 people in the united states suffer damage to peripheral nerves. of the 50,000 operations performed, 50% or less are successful. gliatech, inc. is developing an artificial nerve graft seeded with schwann cells. the current protocol calls for removing a segment of nerve from a… More

Inhibition of B-Amyloid-Induced Complement Activation

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$80,249.00
Agency:
HHS
Principal Investigator:
Suio-Ling Chen
Abstract:
The hallmark of AD is the formation of cerebral senile plaques, with amyloid beta protein (Abeta)as its principle component. There is ample evidence suggesting that complement activation within andaround plaques leads to local inflammation and direct damage to neurons. We have discovered thatAbeta… More

Inhibition of Tendon Adhesions By Adcon-T

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$75,000.00
Agency:
HHS
Principal Investigator:
Emanuel Palatinsky
Abstract:
Scars form after tendon injury. It binds the tendon and prevents it from gliding freely, resultingin diminished movement in a high percentage of patients. Prophylactic application of an agent thatinhibits adhesion formation would improve the outcome of these patients. We have developed a seriesof… More

Development of Novel Chiral Cyclic Histamine H3 Agonists

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
James Phillips
Abstract:
The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develotreatment of acute and chronic insomnia. The Specific Aims of this grant are (1) to synthesize… More

Evaluation of a Novel H3 Antagonist, GT 2016, for Add

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Clark Tedford
Abstract:
N/a

Evaluation of a Novel H3 Antagonist, GT 2016, for Add

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$721,665.00
Agency:
HHS
Principal Investigator:
Clark Tedford
Abstract:
The long-term objectives are to develop novel histamine H3 receptor antagonists to increase wakefuland enhance cognitive abilities. The specific aims of this grant are (1) to test a novel non- thiourfor its ability to increase histamine release in various rat brain regions, including the frontal… More

INHIBITION OF POSTOPERATIVE GYNECOLOGICAL ADHESIONS

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,076.00
Agency:
HHS
Principal Investigator:
Lo, hungnan
Abstract:
N/a

MOLECULAR CHARACTERIZATION--HISTAMINE RECEPTOR SUBTYPES

Award Year / Program / Phase:
1997 / SBIR / Phase I
Award Amount:
$99,535.00
Agency:
HHS
Principal Investigator:
Burgess, loyd h
Abstract:
N/a

Development of Novel Chiral Cyclic Histamine H3 Agonists

Award Year / Program / Phase:
1998 / SBIR / Phase II
Award Amount:
$621,379.00
Agency:
HHS
Principal Investigator:
James Phillips
Abstract:
The long-term objectives are to synthesize novel cyclic and heterocyclic histamine H3 receptor agonprodrugs thereof that have improved GI absorption and CNS penetration. These agents are being develotreatment of acute and chronic insomnia. The Specific Aims of this grant are (1) to synthesize… More

COMBINATORIAL CONSTRUCTION OF NOVEL IMIDAZOLE LIBRARIES

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,832.00
Agency:
HHS
Principal Investigator:
Ali, Syed M
Abstract:
N/a

DEVELOPMENT OF DRUGS FOR SCHIZOPHRENIA AND DEMENTIA

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$97,517.00
Agency:
HHS
Principal Investigator:
Brunden, Kurt R
Abstract:
N/a

ANTIPROPERDIN AGENTS AS NOVEL ANTIINFLAMMATORIES

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$97,516.00
Agency:
HHS
Principal Investigator:
Bansal, Rekha
Abstract:
N/a

N/A

Award Year / Program / Phase:
1999 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Lo hungnan
Abstract:
N/a

NOVEL GLYCINE TRANSPORTER INHIBITORS FOR SCHIZOPHRENIA

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$93,862.00
Agency:
HHS
Principal Investigator:
Abstract:
The glutamate/glycine NMDA receptor has been implicated in a variety of central nervous system disorders and pathological conditions. In particular, NMDA receptor hypofunction may contribute significantly to the cognitive and behavioral deficits in schizophrenia. Glycine binds within the NMDA… More